Arcus Biosciences RCUS Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's business segments — net loss?
- Arcus Biosciences (RCUS) reported business segments — net loss of -$128M in Q1 2026.
- How has Arcus Biosciences's business segments — net loss changed year-over-year?
- Arcus Biosciences's business segments — net loss decreased by 14.3% year-over-year, from -$112M to -$128M.
- What is the long-term trend for Arcus Biosciences's business segments — net loss?
- Over 3 years (2022 to 2025), Arcus Biosciences's business segments — net loss has grown at a 9.8% compound annual growth rate (CAGR), from -$267M to -$353M.
- What does business segments — net loss mean?
- Measures the bottom-line financial performance of the segment after accounting for all revenues and operating expenses. For clinical-stage companies, this metric highlights the burn rate associated with advancing the product pipeline toward regulatory milestones.